Adalimumab (Humira) and ankylosing spondylitis

Abbott's clinical trials into the use of adalimumab (Humira), the third major anti-TNF drug to come to our attention, in the treatment of ankylosing spondylitis show "significant reductions in signs and symptoms, including pain and inflammation, and improved health-related quality of life," the drug company says in a press release. Abbott applied last month to both the FDA and the European Medicines Agency for the right to market Humira as a treatment for ankylosing spondylitis.